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valuable resource to support practitioners and clinics in 
addressing this important aspect of being human. 
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Purpose: A recently published practice-changing multicentre 
randomized study demonstrated no difference in overall survival 
(OS) and progression-free survival (PFS) between a short RT 
(arm1: 25 Gy in five fractions) and standard RT (arm 2: 40 Gy in 
15 fractions) in elderly and/or frail patients with glioblastoma 
multiforme (GBM). The purpose was to compare study arms for 
health-related quality of life (HR-QoL). 
Methods and Materials: EORTC core questionnaire QLQ-C30 and 
the brain module QLQ-BN20 were used to assess HR-QoL at 
baseline prior to RT, four weeks after RT completion and every 
three months thereafter until the disease progression. QoL 
scores over time were examined using generalized estimating 
equation adjusting for the treatment arms.  
Results: Of 98 randomized patients, 96 were eligible for QoL 
analysis. There was no difference in global QoL/main function 
scales/symptoms (except for insomnia) between arms. 
Improvement of global QoL, social and physical function, fatigue 
and insomnia were observed when comparing baseline to four 
months post-treatment, but only significant for insomnia, 
favouring arm 2. Difference of ≥ 10 points from baseline to four 
months was demonstrated for social function and insomnia (arm 
1), physical function (both arms) and fatigue (arm 2). Global QoL 
at baseline was significantly worse for arm 1, but statistically 
insignificant at one month and four months post-radiotherapy. 
Conclusions: There was overall no difference in HR-QoL between 
the two arms. A trend toward significant difference was seen in 
social function, insomnia, and global QoL favouring short RT 
regimen. 
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Purpose: Cancer staging, which consists in objectifying the 
extent of cancer spread, is essential before the initiation of 
therapy. Staging is often incorrectly performed, with a sizeable 
portion of patients receiving unnecessary staging tests, which are 
costly. This study seeks to quantify the cost of such unnecessary 
tests in patients with early-stage breast cancer in the province 
of Québec, Canada. 
Methods and Materials: All patients diagnosed with breast 
cancer between 2012 and 2014 and listed in the tumour registry 
of the McGill University Health Centre, were included in this 
retrospective study. For each patient with early-stage breast 
cancer, the type and number of unnecessary staging tests, as per 
national guideline definitions, was extracted from the medical 
chart. The cost of each test, from a single payer point of view, 
was obtained from the Quebec government manuals of payment 
to physicians and departments. The total cost of unnecessary 
tests for staging of early-stage breast cancer was derived. 
Finally, an extrapolation was done to estimate the total cost for 
the whole province of Québec per year, given the number of 
diagnoses of breast cancer in that province. 
Results: 1845 patients were listed in the tumour registry of the 
MUHC, 1116 of which were diagnosed with early-stage breast 
cancer. 82.5% of patients underwent at least one inappropriate 
staging test, with an average of 2.35 inappropriate tests were 
performed per patient. Less than 1% of these tests detected 
metastatic disease. The average theoretical cost of 
inappropriate staging tests per patient was $235.84, $251.83 and 
$217.34 for 2012, 2013, and 2014 respectively, with an average 
total cost to the government of Québec of $830,659.61 per year, 
and a 10-year cost of $8,306,596.18. 
Conclusions: The majority of patients with early-stage breast 
cancer undergo unnecessary staging tests. In a social system with 
limited resources, these tests are costly to the single payer 
Québec government. 
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Purpose: Radiotherapy (RT) is a highly effective and curative 
treatment for patients with invasive cervical cancer, and is the 
standard of care for locally advanced disease. Although RT can 
be successfully delivered in developing countries, major gaps in 
access have resulted in substantial preventable morbidity and 
mortality, where nearly 90% of cervical cancer deaths occur. 
These gaps are multifactorial, but assumptions about excessive 
cost of RT in these regions preclude effective implementation. 
Using methodology developed for the Global Task Force on 
Radiotherapy for Cancer Control (GTFRCC), we examined the 
validity of these assumptions for the treatment of cervical 
cancer with external beam radiation (EBRT) and brachytherapy 
(BT) in upper middle-income income (UMIC), lower middle-
income (LMIC) and low-income countries (LIC). 
Methods and Materials: Based on the GTFRCC evidence-based 
estimation approach, we assumed that 71% of cervical cancer 
patients would require RT, with a mean of 21 EBRT and three 
HDR BT fractions per course, resulting in a 20% overall survival 
benefit. We developed a decision-analytic Markov model to 
assess three RT capacity scenarios from 2015 to 2035: 1) no 
increase in capacity; 2) linear scale-up from baseline coverage 
in 2015 to universal accessibility by 2035; and 3) immediate full 
availability. Model outcomes included total life years (LYs) and 
economic productivity (US Dollar). Costs, based on the GTFRCC 
efficiency model, and benefits were discounted by 3% annually 
over a lifetime horizon. 
Results: If no action is taken to shift current RT capacity to 
universal accessibility, we project a loss of up to 21.4 million (M) 
